1 September 2023 false No description of principal activity Taxfiler 2024.6 14327803business:PrivateLimitedCompanyLtd2023-09-012024-08-31 143278032023-08-31 143278032023-09-012024-08-31 14327803business:AuditExempt-NoAccountantsReport2023-09-012024-08-31 14327803business:FilletedAccounts2023-09-012024-08-31 143278032024-08-31 14327803business:Director12023-09-012024-08-31 14327803business:Director22023-09-012024-08-31 14327803business:RegisteredOffice2023-09-012024-08-31 143278032023-08-31 14327803core:WithinOneYear2024-08-31 14327803core:WithinOneYear2023-08-31 14327803core:AfterOneYear2024-08-31 14327803core:AfterOneYear2023-08-31 14327803core:ShareCapitalcore:PreviouslyStatedAmount2024-08-31 14327803core:ShareCapitalcore:PreviouslyStatedAmount2023-08-31 14327803core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2024-08-31 14327803core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2023-08-31 14327803core:PreviouslyStatedAmount2024-08-31 14327803core:PreviouslyStatedAmount2023-08-31 14327803business:SmallEntities2023-09-012024-08-31 14327803countries:EnglandWales2023-09-012024-08-31 14327803core:ComputerEquipment2023-09-012024-08-31 14327803core:Goodwill2023-08-31 14327803core:Goodwill2023-09-012024-08-31 14327803core:Goodwill2024-08-31 14327803core:ComputerEquipment2023-08-31 14327803core:ComputerEquipment2024-08-31 143278032022-08-312023-08-31 iso4217:GBP xbrli:pure
Company Registration No. 14327803 (England and Wales)
Weymouth Pharma Ltd Unaudited accounts for the year ended 31 August 2024
Weymouth Pharma Ltd Unaudited accounts Contents
Page
- 2 -
Weymouth Pharma Ltd Company Information for the year ended 31 August 2024
Directors
Sunil Varghese Chacko Moyosoreoluwa Ogunfowoke
Company Number
14327803 (England and Wales)
Registered Office
19 Fuchsia Gardens Southampton SO16 6TY United Kingdom
- 3 -
Weymouth Pharma Ltd Statement of financial position as at 31 August 2024
2024 
2023 
Notes
£ 
£ 
Fixed assets
Intangible assets
625,080 
233,094 
Tangible assets
3,966 
4,280 
629,046 
237,374 
Current assets
Inventories
89,000 
81,500 
Debtors
153,882 
59,983 
Cash at bank and in hand
27,363 
30,733 
270,245 
172,216 
Creditors: amounts falling due within one year
(409,954)
(227,265)
Net current liabilities
(139,709)
(55,049)
Total assets less current liabilities
489,337 
182,325 
Creditors: amounts falling due after more than one year
(488,000)
(181,210)
Net assets
1,337 
1,115 
Capital and reserves
Called up share capital
100 
100 
Profit and loss account
1,237 
1,015 
Shareholders' funds
1,337 
1,115 
For the year ending 31 August 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board of Directors and authorised for issue on 10 May 2025 and were signed on its behalf by
Sunil Varghese Chacko Director Company Registration No. 14327803
- 4 -
Weymouth Pharma Ltd Notes to the Accounts for the year ended 31 August 2024
1
Statutory information
Weymouth Pharma Ltd is a private company, limited by shares, registered in England and Wales, registration number 14327803. The registered office is 19 Fuchsia Gardens, Southampton, SO16 6TY, United Kingdom.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Intangible fixed assets
Intangible fixed assets (including purchased goodwill and patents) are included at cost less accumulated amortisation.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Computer equipment
20% reduce balance basis
4
Intangible fixed assets
Goodwill 
£ 
Cost
At 1 September 2023
237,045 
Additions
397,389 
At 31 August 2024
634,434 
Amortisation
At 1 September 2023
3,951 
Charge for the year
5,403 
At 31 August 2024
9,354 
Net book value
At 31 August 2024
625,080 
At 31 August 2023
233,094 
- 5 -
Weymouth Pharma Ltd Notes to the Accounts for the year ended 31 August 2024
5
Tangible fixed assets
Computer equipment 
£ 
Cost or valuation
At cost 
At 1 September 2023
5,350 
Additions
677 
At 31 August 2024
6,027 
Depreciation
At 1 September 2023
1,070 
Charge for the year
991 
At 31 August 2024
2,061 
Net book value
At 31 August 2024
3,966 
At 31 August 2023
4,280 
6
Debtors
2024 
2023 
£ 
£ 
Amounts falling due within one year
VAT
40,967 
21,864 
Trade debtors
112,915 
38,119 
153,882 
59,983 
7
Creditors: amounts falling due within one year
2024 
2023 
£ 
£ 
Trade creditors
153,002 
44,312 
Taxes and social security
2,335 
1,247 
Other creditors
14,856 
9,982 
Loans from directors
239,761 
171,524 
Accruals
- 
200 
409,954 
227,265 
8
Creditors: amounts falling due after more than one year
2024 
2023 
£ 
£ 
Bank loans
488,000 
181,210 
9
Average number of employees
During the year the average number of employees was 14 (2023: 4).
- 6 -